Galantamine chemical structure Scheme 1. Trost 2005 Galanthamine total synthesis:a bromine, sodium acetate, acetic acid, iron, rt b potassium carbonate, 2days c  Troc-Cl, DMAP, Pyridine, dichloromethane d palladium,Trost ligand, triethylamine, dichloromethane e 1.5 mol % TsOH, CH(OMe)3, methanol f DIBAL-H, toluene, -78 °C, 1 hr g  triphenylphosphine, acetonecyanohydrin, DIAD, diethyl ether h 2.20 mol % TsOH, THF, water i  15 mol % Palladium(II) acetate, 15 mol% dppp, 3 eq. Ag2CO3, toluene, 107 °C j selenium dioxide  disodium hydrogen phosphate dioxane, 150 °C 3 hrs k  methylamine ,methanol l 4 eq. DIBAL-H, m aqueous NaH2PO4 n NaCNBH3
Find information on thousands of medical conditions and prescription drugs.

Galantamine

Galantamine (trade name Razadyne®, Reminyl®) is a medication used in the treatment of Alzheimer's disease. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
Gabapentin
Gabitril
Galantamine
Gamma-hydroxybutyrate
Ganciclovir
Garamycin
Gaviscon
Gemcitabine
Gemfibrozil
Gemhexal
Gemzar
Generlac
Gentamicin
Geodon
Gleevec
Gliadel
Gliadel Wafer
Glibenclamide
Glimepiride
Glipizide
Glucagon
Glucobay
Glucohexal
Glucophage
Glucosamine
Glucotrol
Glutethimide
Golytely
Gonadorelin
Goserelin
Gramicidin
Gramicidin S
Granisetron
Grifulvin V
Griseofulvin
Guaifenesin
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Galantamine is mostly used as hydrobromide salt. It is a centrally acting reversible cholinesterase inhibitor in the same class as donepezil. Galantamine has a much shorter half life than donepezil (there is a newer prolonged release version available in 2004) and it also has more nicotinic receptor activity and is potentially more stimulating but also probably because of this activity tends to cause worse gastrointestinal side effects.

Total synthesis

The natural source of galantamine are certain species of daffodil and because these species are scarce and because the isolation of galanthamine from daffodil is expensive (a 1996 figure specifies 50,000 US dollar per kilogram) alternative synthetic sources are under development by means of total synthesis. One recent publication details the enantioselective organic synthesis of galanthamine and also that of morphine from a single precursor .

The total synthesis of galanthamine (Trost 2005) is described as follows (see scheme 1): the sequence starts by bromination by electrophilic aromatic substitution of isovanillin 1 to bromophenol 2, then by synthesis of the second intermediate 5 by reacting dialdehyde 3 in a coupled aldol reaction and Horner-Wadsworth-Emmons reaction with trimethyl phosphonoacetate 4. The hydroxyl group is activated as a leaving group by acetylation with trichloroethyl carbonate (Troc) to 6. Next an enantioselective Trost AAA reaction takes place between bromophenol 2 and carbonate 6 to the allyl ether 7. Next the aldehyde group is protected as an acetal in 8 and this step enables the to organic reduction of the ester group to the alcohol 9 with DIBAH and subsequent conversion of this alcohol to a nitrile by nucleophilic displacement to 10 followed by aldehyde deprotection to 11. The intramolecular Heck reaction to 12 creates the dihydrofuran ring. Allylic oxidation by selenium dioxide provides allylic alcohol 13 with the correct stereochemistry. The aldehyde reacts with methylamine to the imine 14 and reduction of the imine and nitrile by DIBAL-H leading to ring-closure to the hemi-aminal 15 (not isolated) followed by acid quenching gives the alcohol 16. In the final step this alcohol group is reduced to give Galanthamine 17 together with 6% of the epi isomer 18.

Read more at Wikipedia.org


[List your site here Free!]


Barr Laboratories
From Drug Store News, 8/22/05

Barr Laboratories received final FDA approval for its fexofenadine HC1 capsules in 60 mg strength, the generic version of Aventis Pharmaceuticals' Allegra, indicated for the relief of symptoms associated with seasonal allergic rhinitis and for treating uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children. Barr is entitled to 180 days of marketing exclusivity on the product.

In other news, Barr received final FDA approval for its generic version of DDAVP (desmopressin acetate) tablets in 0.1 mg and 0.2 mg dosages. Barr is the first to file an ANDA and is entitled to 180 days of marketing exclusivity. DDAVP tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. They also are indicated for the management of primary nocturnal enuresis. DDAVP had annual branded sales of $191 million per IMS Health data for the 12 months ended in April.

Barr also confirmed that Janssen Pharmaceutica Products and Synaptech filed suit against the company relating to the patents protecting Razadyne (galantamine hydrobromide), formerly called Reminyl, in 4 mg, 8 mg and 12 mg tablets. The drug is indicated for treating mild to moderate dementia of the Alzheimer's type. The suit officially initiates the patent challenge process under the Hatch-Waxman Act. Razadyne had annual branded sales of $247 million for the 12 months ended in April, according to IMS Health data.

COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group

Return to Galantamine
Home Contact Resources Exchange Links ebay